The purpose of this trial is to compare three doses of ACR16 and determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
Wednesday, October 21, 2009
A Study of ACR16 for the Treatment of Patients With Huntington's Disease (HART) in Canada
Posted by Heather Dugdale at 7:42 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment